Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Q3 Revenue Up 8 Percent; Sales of Genomic, Proteomic Tools Strong

NEW YORK, Oct. 29 (GenomeWeb News) - Beckman today reported sales of $581 million for the third quarter, up over $535 million one year ago.


The company's Biomedical Research Division, which sells the GenomeLab and ProteomeLab instruments, increased by 5 percent year over year. Clinical Diagnostics, by comparison, was up 10 percent.


R&D spending for the period increased to $51.5 million from $46.5 million. Net earnings for the quarter jumped to $57 million, or $.93 per basic earnings per share, from $40 million, or $.65 per basic earnings per share, for the same quarter in 2003.


The company reported cash and cash equivalents of $31 million on hand as of Sept. 30.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.